SMS Pharmaceuticals Ltd has received a tax demand of ₹456.3 million from Indian tax authorities. This significant tax liability comes at a time when the company had been projecting strong growth, having previously reiterated its guidance of achieving 20% revenue growth for fiscal year 2025. The tax demand may impact the company's financial outlook and growth plans. SMS Pharmaceuticals, known for its active pharmaceutical ingredients manufacturing, had reported robust performance in recent quarters, with a 44% revenue growth and 235% profit increase in Q1 FY22. The company's response to this tax demand and its potential impact on future projections will be closely watched by investors and industry analysts.
Source: NSE, BSE, and Company Filings